Page 215 - Read Online

Here, we highlight the importance that have these miRNAs JE, Ratziu V, McCullough A. Endpoints and clinical trial design for
as repressor of factors coordinating the cell fate by triggering nonalcoholic steatohepatitis. Hepatology 2011;54:344-53.
pro-death mechanisms e.g. apoptosis and autophagy. 5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 2004;116:281-97.
6. Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC
In particular, the authors reported that AMP-activated protein couples microRNA biogenesis and posttranscriptional gene silencing.
kinase (AMPK) is a target of the majority of the identified Cell 2005;123:631-40.
miRNAs. AMPK is responsible of metabolic processes as 7. Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW, Kellum
mentioned by the authors, thus conferring it also a key JM, Min H, Luketic VA, Sanyal AJ. Nonalcoholic steatohepatitis is
associated with altered hepatic microRNA expression. Hepatology
role during autophagy. In particular, AMPK is responsible 2008;48:1810-20.
[12]
of ULK1 (serine/threonine-protein kinase) phosphorylation 8. Pogribny IP, Starlard-Davenport A, Tryndyak VP, Han T, Ross SA,
with consequent mammalian target of rapamycin complex Rusyn I, Beland FA. Difference in expression of hepatic microRNAs
(mTORC) inhibition and autophagy activation during miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-
nutrient starvation. Autophagy represents a fine regulated specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab
[12]
Invest 2010;90:1437-46.
mechanism to overcome cellular stress and promote cell 9. Alisi A, Da Sacco L, Bruscalupi G, Piemonte F, Panera N, De Vito R,
death in case of protracted cellular stress. It has been Leoni S, Bottazzo GF, Masotti A, Nobili V. Mirnome analysis reveals
shown that its modulation can be a promising target for novel molecular determinants in the pathogenesis of diet-induced
nonalcoholic fatty liver disease. Lab Invest 2011;91:283-93.
cancer therapy in liver cancer. The expression of miRNAs 10. Choi SE, Fu T, Seok S, Kim DH, Yu E, Lee KW, Kang Y, Li X, Kemper
[13]
repressing autophagy regulators like AMPK could highlight B, Kemper JK. Elevated microRNA-34a in obesity reduces NAD+
the variations occurring at epigenetic level conferring to cells levels and SIRT1 activity by directly targeting NAMPT. Aging Cell
an altered metabolism that irreversibly modifies the liver cells 2013;12:1062-72.
and tissue. These alterations could be responsible to trigger 11. Okamoto K, Koda M, Okamoto T, Onoyama T, Miyoshi K, Kishina M,
further pathological cellular features leading to cirrhosis and Kato J, Tokunaga S, Sugihara TA, Hara Y, Hino K, Murawaki Y. A series
of microrna in the chromosome 14q32.2 maternally imprinted region
furthermore liver carcinogenesis. [14,15] For this reason it will be related to progression of non-alcoholic fatty liver disease in a mouse
interesting to further focus on the expression of the miRNAs model. PLoS One 2016;11:e0154676.
localized at mat 14q32.2 in patients affected by cirrhosis and 12. Ha J, Guan KL, Kim J. AMPK and autophagy in glucose/glycogen
liver cancer, as it has been already shown for other miRNAs metabolism. Mol Aspects Med 2015;46:46-62.
in liver cancer cells and thyroid cancer. [16-18] The miRNAs 13. Di Fazio P, Waldegger P, Jabari S, Lingelbach S, Montalbano R, Ocker M,
Slater EP, Bartsch DK, Illig R, Neureiter D, Wissniowski TT. Autophagy-
discovered in this study can represent valid targets for the related cell death by pan-histone deacetylase inhibition in liver cancer.
diagnosis of NAFLD and could be furthermore adopted as Oncotarget 2016; doi: 10.18632/oncotarget.8585.
biomarkers for patients affected by cirrhosis and liver cancer. 14. Mahgoub A, Steer CJ. MicroRNAs in the evaluation and potential
treatment of liver diseases. J Clin Med 2016;5:52.
Finally, inhibition of mTORC by the use of biguanides 15. Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects
of initiation and progression of hepatocellular carcinoma. World J
[19]
(metformin), a well known mTOR inhibitors currently Gastroenterol 2015;21:10584-97.
used for the treatment of type 2 diabetes, could represent 16. Damanakis AI, Eckhardt S, Wunderlich A, Roth S, Wissniowski TT,
[20]
a therapeutic target for NASH in a translational setting Bartsch DK, Di Fazio P. MicroRNAs let7 expression in thyroid cancer:
[21]
defining mTORC as a major target of NASH related miRNA. correlation with their deputed targets HMGA2 and SLC5A5. J Cancer
Res Clin Oncol 2016;142:1213-20.
17. Henrici A, Montalbano R, Neureiter D, Krause M, Stiewe T, Slater EP,
Financial support and sponsorship Quint K, Ocker M, Di Fazio P. The pan-deacetylase inhibitor panobinostat
Nil. suppresses the expression of oncogenic miRNAs in hepatocellular
carcinoma cell lines. Mol Carcinog 2015;54:585-97.
Conflicts of interest 18. Di Fazio P, Montalbano R, Neureiter D, Alinger B, Schmidt A, Merkel
There are no conflicts of interest. AL, Quint K, Ocker M. Downregulation of HMGA2 by the pan-
deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression
in liver cancer cell lines. Exp Cell Res 2012;318:1832-43.
REFERENCES 19. Khawaja MR, Nick AM, Madhusudanannair V, Fu S, Hong D, McQuinn
LM, Ng CS, Piha-Paul SA, Janku F, Subbiah V, Tsimberidou A, Karp D,
1. Basaranoglu M, Basaranoglu G, Sabuncu T, Senturk H. Fructose as a key Meric-Bernstam F, Lu KH, Naing A. Phase I dose escalation study of
player in the development of fatty liver disease. World J Gastroenterol temsirolimus in combination with metformin in patients with advanced/
2013;19:1166-72. refractory cancers. Cancer Chemother Pharmacol 2016;77:973-7.
2. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 20. Provinciali N, Lazzeroni M, Cazzaniga M, Gorlero F, Dunn BK, DeCensi
1998;114:842-5. A. Metformin: risk-benefit profile with a focus on cancer. Expert Opin
3. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic Drug Saf 2015;14:1573-85.
fatty liver disease: the multiple parallel hits hypothesis. Hepatology 21. Xu H, Zhou Y, Liu YX, Ping J, Shou QY, Chen FM, Ruo R. Metformin
2010;52:1836-46. improves hepatic IRS2/PI3K/Akt signaling in insulin resistant rats of
4. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine NASH and cirrhosis. J Endocrinol 2016;229:133-44.

206 Hepatoma Research | Volume 2 | July 13, 2016